Trials / Completed
CompletedNCT02427516
Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,144 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate annualized total cost rates (i.e. direct medical costs from hospitalizations, consultations, medications, and tests) of adequately controlling a patient (i.e. INR between 2-3 and TTR≥ 60%) diagnosed with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE), and treated with vitamin K antagonists (VKA) in Spain.
Conditions
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2015-05-01
- Completion
- 2015-11-01
- First posted
- 2015-04-28
- Last updated
- 2016-09-20
Source: ClinicalTrials.gov record NCT02427516. Inclusion in this directory is not an endorsement.